- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04126772
Multimodal Imaging of MS Reveals the Smoldering Inflammation (PLAQ-MS)
Study Overview
Status
Conditions
Detailed Description
Objective: To establish the QSM-MRI-method as a part of MS-patient research protocol in TPC and to quantify the time and space dependent correlation of QSM-MRI signal and PET-imaging signal with both 11C-PK11195 and 11C-SMW139 radioligands in the brain of MS-patients with active disease, secondary progressive MS-patients and healthy controls.
Background: In MS brain the inflammatory lesions change over time from active to chronic active and finally to chronic inactive plaques. Conventional MRI-imaging is used to detect the lesions but it is not able to differentiate the plaque types. The most acute lesions with blood-brain-barrier defect can be identified using conventional MRI and gadolinium enhancing, but follow-up of the later plaque development with microglial activation at plaque edge is not possible using MRI. Furthermore, the diffuse microglial activation in the NAWM is not detectable with conventional MRI.
In previous studies it has been shown that chronic active plaques have a rim of active microglial cells around them. With QSM-MRI method it is possible to detect and quantify these iron containing active microglia cells around the chronic active plaque. Active microglial cells can also be detected with PET imaging and TSPO-binding radioligand 11C-PK11195 or P2X7 binding radioligand 11C-SMW139. The investigators expect that the microglial activation signals detected with QSM-MRI and PET are co-localized and that these methods would help to differentiate the plaque types and to evaluate the MS plaque evolution.
Study population: 10 MS-patients with acute gadolinium enhancing ≥0,5cm diameter lesion will be imaged at baseline and 4 and 18 months after that. For comparison 10 secondary progressive patients and 20 healthy controls will be imaged at baseline.
Methods: Clinical evaluation, brain QSM-MRI and PET imaging with 11C-PK11195 radiotracer will be performed at baseline, 4 months and 18 months. PET imaging with 11C-CSMW139 radiotracer will be performed at 4 months and 18 months.
For healthy controls, brain QSM-MRI, PET imaging with 11C-PK11195 radiotracer and PET imaging with 11C-SMW139 radiotracer will be performed at baseline. For 12 healthy controls a test-retest imaging with 11C-SMW139 radiotracer will be performed.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Locations
-
-
Finland Proper
-
Turku, Finland Proper, Finland, 20520
- Recruiting
- Turku PET Centre
-
Contact:
- Laura Airas, MD,Professor
- Phone Number: 023130000
- Email: laura.airas@utu.fi
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria
Active MS-patients:
- Informed consent form
- At least one 0,5 cm diameter active gadolinium enhancing lesion detected lately
- Diagnosed MS-disease according to McDonald criteria
SPMS patients
- Informed consent form
- Diagnosed MS-disease according to McDonald criteria
- SPMS disease
Healthy controls:
- Informed consent form
- healthy
- age and sex matched with MS-patients in RRMS and SPMS groups
Exclusion Criteria
MS-patients:
- Patients suffering from another brain disease or other autoimmune disease in addition to multiple sclerosis
- Steroid treatment 4 weeks prior to the scan
- Significant pathology in the MRI scan other than MS-related lesions
- Patients suffering from claustrophobia or panic disorder, or patients who have exhibited hypersensitivity of PET markers (practical obstacle to the scan)
- Exposure to experimental radioactivity in the last 12 months such that the dosimetry threshold would be exceeded due to participation in the study
- Age over 70
Healthy controls:
- autoimmune disease, CNS disease or other serious disease
- Steroid treatment 4 weeks prior to the scan or other regular medication
- persons suffering from claustrophobia or panic disorder, or persons who have exhibited hypersensitivity of PET markers (practical obstacle to the scan)
- Exposure to experimental radioactivity in the last 12 months such that the dosimetry threshold would be exceeded due to participation in the study
- Age over 70
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
---|
Active MS patients
10 MS patients with an active lesion of 0,5 cm diameter
|
Healthy controls
20 healthy controls
|
SPMS patients
10 SPMS patients
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
11C-PK11195 binding in MS patient brain
Time Frame: Baseline, 4 months 18 months
|
Change in microglia-activity in MS patients during 18 months as measured by [11C]PK11195 PET imaging
|
Baseline, 4 months 18 months
|
11C-SMW139 binding in MS patient brain
Time Frame: Baseline, 4 months 18 months
|
Change in microglia-activity in MS patients during 18 months as measured by [11C]SMW139 PET imaging
|
Baseline, 4 months 18 months
|
QSM-signal in MS patient brain
Time Frame: Baseline, 4 months 18 months
|
Change in microglia-activity in MS patients during 18 months as measured by QSM-MRI
|
Baseline, 4 months 18 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
11C-PK11195 binding in healthy control brain
Time Frame: Baseline
|
Change in microglia-activity in healthy controls during 18 months as measured by PET imaging and [11C]PK11195
|
Baseline
|
11C-SMW139 binding in healthy control brain
Time Frame: Baseline
|
Change in microglia-activity in healthy controls during 18 months as measured by PET imaging [11C]SMW139
|
Baseline
|
QSM-signal in healthy control brain
Time Frame: Baseline
|
Change in microglia-activity in healthy controls during 18 months as measured by QSM-MRI
|
Baseline
|
MRI metrics
Time Frame: Baseline, 4 months, 18 months
|
To evaluate lesion load of the white matter MS plaques
|
Baseline, 4 months, 18 months
|
EDSS
Time Frame: Baseline, 4 months, 18 months
|
Expanded Disability Status Scale.
The scale ranges from 0 to 10 in 0.5 unit increments that represent higher levels of disability.
|
Baseline, 4 months, 18 months
|
MSFC
Time Frame: Baseline, 4 months, 18 months
|
Multiple Sclerosis Composite Score which consists of three assessments of walking speed, processing speed and finger dexterity.
The scores are combined to provide a Z-score.
Lower scores represent greater abnormality.
|
Baseline, 4 months, 18 months
|
Fatigue severity scale
Time Frame: Baseline, 4 months, 18 months
|
Fatigue Severity Scale is a self-reported, 9-item fatigue scale.
Participants rate all 9 items on a 7-point Likert scale (1-2-3-4-5-6-7) depending on how appropriate they felt the statement applied to them over the preceding week.
The total score is calculated by adding up the answer from each item and divide by 9. Lower scores indicate better outcomes.
Maximum score is 7.
|
Baseline, 4 months, 18 months
|
Modified Fatigue Impact Scale
Time Frame: Baseline, 4 months, 18 months
|
The Modified Fatigue Impact Scale is a self-report survey that contains 21 items.
Each item is rated 0-4.
Higher scores indicate a greater impact of fatigue on a person's activities.
|
Baseline, 4 months, 18 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Laura Airas, MD,professor, Turku University Hospital, division of clinical neurosciences
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PLAQ-MS
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Sclerosis
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationRecruitingMultiple Sclerosis (MS) | Relapsing-remitting Multiple Sclerosis (RRMS) | Secondary-progressive Multiple Sclerosis (SPMS) | Primary Progressive Multiple Sclerosis (PPMS)Switzerland
-
University of California, Los AngelesUnknownRelapsing-remitting Multiple Sclerosis | Secondary-progressive Multiple Sclerosis | Primary-progressive Multiple SclerosisUnited States
-
BiogenCompletedMultiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent ProgressiveJapan
-
The Cleveland ClinicUniversity Hospitals Cleveland Medical CenterCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
Rigshospitalet, DenmarkOdense University Hospital; Aarhus University Hospital; Hvidovre University Hospital and other collaboratorsRecruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisDenmark
-
University of California, San FranciscoUnited States Department of DefenseRecruitingMultiple Sclerosis, Chronic Progressive | Multiple Sclerosis, Relapsing-Remitting | Multiple Sclerosis (MS) | Multiple Sclerosis Relapse | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis Brain Lesion | Multiple Sclerosis BenignUnited States
-
Icahn School of Medicine at Mount SinaiColumbia University; New York Stem Cell Foundation Research InstituteCompletedClinically Isolated Syndrome | Relapsing-Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Banc de Sang i TeixitsVall d'Hebron Research Institute (VHIR)CompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisSpain
-
BiogenElan PharmaceuticalsCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Queen Mary University of LondonTakeda Pharmaceuticals International, Inc.RecruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited Kingdom